MedTrace Logo

Long-Term Renoprotection of Optimal Antiproteinuric Doses of Benazepril and Losartan in Chronic Renal Insufficiency

NCT00338091 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL

Last updated 2006-06-20

No results posted yet for this study

Summary

The primary goal of the trial was to evaluate whether the optimal antiproteinuric doses of benazepril (an ACE inhibitor) or losartan (an ARB), as compared with their conventional doses, can safely improve the long-term renal outcome in nondiabetic patients with proteinuria and chronic renal insufficiency. The second aim was to compare the long-term renal protection between benazepril and losartan at similar clinical setting.

Conditions

  • Renal Insufficiency,Chronic
  • Disease Progression
  • Proteinuria
  • Dose-Response Relationship,Drug
  • ACE Inhibitor
  • Angiotensin II Type 1 Receptor Blockers

Interventions

DRUG

Benazepril

DRUG

Losartan

Sponsors & Collaborators

  • Southern Medical University, China

    lead OTHER

Principal Investigators

  • Fan Fan Hou, M.D.,Ph.D. · Division of Nephrology, Nanfang Hospital,Southern Medical University,China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31
Completion
2006-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00338091 on ClinicalTrials.gov